Search

Corvus Pharmaceuticals Inc

Geschlossen

13.33 -4.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.93

Max

13.91

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+111.77% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

86M

1.2B

Vorheriger Eröffnungskurs

17.5

Vorheriger Schlusskurs

13.33

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2026, 23:56 UTC

Compass Minerals International Inc shares are lower in after-market hours, with no specific news identified. Broader market expectations for an interest rate hike persist.

8. Sept. 2026, 23:56 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, despite fluctuations, and remain above their 20-day moving average.

8. Sept. 2026, 23:56 UTC

NextDecade Corp shares gained slightly in after-market trading. The stock remains above its 20-day moving average amid broader economic influences.

8. Sept. 2026, 23:56 UTC

Arrow Financial Corp shares are lower in after-market hours with no specific news identified. The stock has recovered from an initial decline.

8. Sept. 2026, 23:56 UTC

Qualys Inc shares are lower in after-market trading amid broader market weakness. The stock has declined for three consecutive sessions.

8. Sept. 2026, 23:56 UTC

Correlated Moves

Illinois Tool Works Inc shares are lower in after-market trading, reflecting broader industrial sector trends and influenced by declines in Lincoln Electric Holdings Inc.

8. Sept. 2026, 23:56 UTC

PPL Corp shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report that raised interest rate hike expectations.

8. Sept. 2026, 23:56 UTC

Correlated Moves

Samsara Inc shares are lower in after-market hours, influenced by ServiceTitan Inc's significant drop and broader market concerns over potential interest rate hikes.

8. Sept. 2026, 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

8. Sept. 2026, 23:56 UTC

Mastercraft Boat Holdings Inc. shares were roughly flat in after-market hours, reflecting minimal price movement amid ongoing performance challenges.

8. Sept. 2026, 23:56 UTC

Comcast Corp shares are lower in after-market trading, following a session low. Recent economic data has influenced market expectations for potential interest rate hikes.

8. Sept. 2026, 23:56 UTC

Brown & Brown Inc shares are lower in after-market hours, reflecting broader market concerns over a potential interest rate hike following a strong jobs report.

8. Sept. 2026, 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

8. Sept. 2026, 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

8. Sept. 2026, 23:52 UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

8. Sept. 2026, 23:52 UTC

Cardinal Health Inc shares are lower in after-market hours, with volatility noted despite no specific company news or developments influencing the decline.

8. Sept. 2026, 23:51 UTC

CVR Energy Inc shares are higher in after-market trading, recovering from earlier volatility. Rising crude oil prices may be influencing market dynamics.

8. Sept. 2026, 23:51 UTC

Harley-Davidson Inc shares are higher in after-market trading, reflecting volatility amid rising crude oil prices and inflation concerns following a strong jobs report.

8. Sept. 2026, 23:51 UTC

Huron Consulting Group Inc shares are lower in after-market trading, retracing from an earlier session high and remaining below the 20-day moving average.

8. Sept. 2026, 23:51 UTC

Range Resources Corp shares are higher in after-market trading, buoyed by rising crude oil prices nearing $99 per barrel and a strong jobs report.

8. Sept. 2026, 23:51 UTC

Gold Resource Corp shares are lower in after-market hours amid rising crude oil prices and inflation concerns ahead of the Federal Reserve meeting.

8. Sept. 2026, 23:51 UTC

Brazil's Retail Sales MoM report on September 15, 2026, expected to reveal consumer spending trends and impact economic growth outlook.

8. Sept. 2026, 23:51 UTC

South Korea's unemployment rate drops to 2.7% in August, signaling strong job growth and positive investor sentiment amidst global economic uncertainties.

8. Sept. 2026, 23:51 UTC

Japan's July Machinery Orders Expected to Reflect Positive Capital Spending Trends Amidst Economic Recovery and Investor Optimism

8. Sept. 2026, 23:51 UTC

Japan's Trade Balance Data Release on September 15, 2026: Market Braces for Persistent Deficits Amid Weak Yen and Geopolitical Tensions.

8. Sept. 2026, 23:51 UTC

Japan's upcoming exports data release on September 15, 2026, is anticipated to reflect continued reliance on high-tech products amid positive economic indicators and rising real wages, despite global market uncertainties.

8. Sept. 2026, 23:51 UTC

Ambarella Inc. showed unusual strength in after-market trading, advancing despite rising crude oil prices and inflation concerns. No specific news was identified for the move.

8. Sept. 2026, 23:51 UTC

ETSY Inc. shares are higher in after-market trading, despite remaining below the 20-day moving average and near the lower end of the one-month range.

8. Sept. 2026, 23:51 UTC

Shares of United Airlines Holdings Inc. are higher in after-market trading, though they remain below the 20-day moving average and near the one-month range low.

8. Sept. 2026, 23:51 UTC

Illumina Inc shares are higher in after-market trading, showing notable activity and positioning above the 20-day moving average amid a lack of specific news.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

111.77% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  111.77%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat